# Read the claim. Trace the chain.

> About — Research Peptide Fundamentals Research Peptides — About Radiant Peptide Supply, an independent Research Peptide Fundamentals research peptides digest organized around specifications, custody, assays, and evidence limits.

**EDITORIAL PROTOCOL**

An independent briefing desk for compound identity, evidence maturity, documentation quality, and the limits of each conclusion.

## What this desk is

Radiant Peptide Supply is an independent literature digest covering GHK-Cu, tesamorelin, KPV, and retatrutide. Despite the domain name, it does not sell, source, broker, or recommend peptides. “Supply” is treated as a documentation problem: what a material is represented to be, which records attach to it, how a sample moved, what an assay tested, and whether the literature actually applies.

The editorial frame is intentionally clinical. Each compound brief opens in plain English, then moves through identity, mechanism, research findings, reported experience where the corpus supports it, cautions, and documentation priorities. The comparison page puts evidence maturity beside supply-chain questions so a strong trial result is not mistaken for a quality certificate, and a clean assay is not mistaken for clinical efficacy.

## How the evidence is graded

The desk keeps evidence types visible. Cell experiments can define pathways. Animal models can test a biological idea in a living system. Ex vivo work can measure behavior in human tissue outside the body. Controlled human trials can estimate outcomes in a defined population under a protocol. Reviews can synthesize those findings but do not convert weak primary data into strong data.

Numbers remain attached to citations and study context. Community reports are included only when the composed corpus provides them and are labeled **anecdotal, not clinical evidence**. They may identify questions worth studying, but they cannot establish frequency, causation, efficacy, or safety. Regulatory status is reported separately from biological plausibility. Approved tesamorelin, preclinical KPV, investigational retatrutide, and topical-focused GHK-Cu should never be flattened into one category.

## How the documentation is read

Specifications, certificates, custody records, and independent assays do different work. A specification defines what is expected. A certificate states results for a lot. Custody ties a sample to the material represented. An independent assay measures a selected attribute with a stated method. No single document proves identity, purity, concentration, sterility, stability, and biological performance at once.

The desk looks for traceability between these layers. Lot identifiers should agree. Methods should fit the claim. Dates and handling conditions should make sense. Independence should be stated rather than implied. Missing links are described as missing, not filled with assumptions. The same standard is applied to publications: molecule, form, formulation, model, population, and endpoint must match before a result is transferred.

## Editorial boundaries

This is not a clinic and does not provide diagnosis, prescribing, reconstitution instructions, human dosing, or individualized advice. It does not authenticate products or vendors. A posted document can be incomplete, altered, detached from a lot, or technically unsuited to the claim; evaluating it fully may require direct laboratory and regulatory access that an editorial site does not have.

Corrections are part of the method. Notes that identify a page, disputed passage, and primary supporting source can be sent through the [contact desk](/contact). The shared [reference register](/references) exposes the source list so readers can inspect the record directly.

---

An independent clinical-style digest tracing peptide claims from specification to assay to literature—not a vendor, laboratory certificate, or source of medical advice.